Abstract
The intestinal microbiota is firmly implicated not only in the pathogenesis of inflammatory bowel disease (IBD) but increasingly also in the development of inflammation at extraintestinal tissue sites. Significant clinical, genetic, immunological, and microbiological overlap exists between IBD and spondyloarthritis (SpA), which indicates that pathophysiological mechanisms are shared between these diseases and may center on the intestinal microbiota. Recently, culture-independent techniques have enabled the microbiota in health and disease to be described in increasing detail. Moreover, functional studies have identified myriad host effector and regulatory pathways that shape or are shaped by this microbial community. We consider the complex relationship between SpA pathogenesis and gut microbes, with a discussion of how manipulation of the gut microbiota itself may be a promising future target for SpA therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 687-702 |
Number of pages | 16 |
Journal | Best Practice and Research: Clinical Rheumatology |
Volume | 28 |
Issue number | 5 |
DOIs | |
State | Published - 2014 |
Externally published | Yes |
Keywords
- Ankylosing spondylitis
- Dysbiosis
- Inflammatory bowel disease
- Microbiota
- Reactive arthritis
- Spondyloarthritis
ASJC Scopus subject areas
- Rheumatology